HomeCompareATNX vs PEP

ATNX vs PEP: Dividend Comparison 2026

ATNX yields 984.74% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATNX wins by $16481956.90M in total portfolio value
10 years
ATNX
ATNX
● Live price
984.74%
Share price
$0.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$16481957.04M
Annual income
$13,737,663,418,719.40
Full ATNX calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — ATNX vs PEP

📍 ATNX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATNXPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATNX + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATNX pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATNX
Annual income on $10K today (after 15% tax)
$83,702.61/yr
After 10yr DRIP, annual income (after tax)
$11,677,013,905,911.49/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, ATNX beats the other by $11,677,013,851,995.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATNX + PEP for your $10,000?

ATNX: 50%PEP: 50%
100% PEP50/50100% ATNX
Portfolio after 10yr
$8240978.59M
Annual income
$6,868,831,741,074.95/yr
Blended yield
83.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

ATNX
Analyst Ratings
5
Buy
5
Hold
Consensus: Buy
Altman Z
-7.5
Piotroski
4/9
PEP
Analyst Ratings
1
Strong
15
Buy
28
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATNX buys
0
PEP buys
0
No recent congressional trades found for ATNX or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATNXPEP
Forward yield984.74%3.66%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$16481957.04M$144.7K
Annual income after 10y$13,737,663,418,719.40$63,430.49
Total dividends collected$16271814.37M$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: ATNX vs PEP ($10,000, DRIP)

YearATNX PortfolioATNX Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$109,174$98,473.66$10,854$514.44+$98.3KATNX
2$1,121,557$1,004,741.08$11,982$758.21+$1.11MATNX
3$10,846,656$9,646,590.10$13,526$1,136.44+$10.83MATNX
4$98,795,506$87,189,583.88$15,727$1,741.93+$98.78MATNX
5$847,913,243$742,202,051.48$19,012$2,750.28+$847.89MATNX
6$6,860,496,352$5,953,229,181.85$24,173$4,514.44+$6860.47MATNX
7$52,357,357,343$45,016,626,246.62$32,789$7,793.80+$52357.32MATNX
8$377,100,961,928$321,078,589,571.04$48,258$14,354.51+$377100.91MATNX
9$2,564,760,394,425$2,161,262,365,161.88$78,586$28,686.63+$2564760.32MATNX
10$16,481,957,040,754$13,737,663,418,719.40$144,688$63,430.49+$16481956.90MATNX

ATNX vs PEP: Complete Analysis 2026

ATNXStock

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

Full ATNX Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this ATNX vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATNX vs SCHDATNX vs JEPIATNX vs OATNX vs KOATNX vs MAINATNX vs MOATNX vs PMATNX vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.